Built Environment Biohardening
Transform buildings into pathogen-resistant spaces through improved air filtration, germicidal lighting, and emergency air disinfection measures.
Last updated: May 11, 2026 · Public updates are batched quarterly, with urgent corrections as needed.
5-year budget target
Pillar
Five-Year Trajectory
2026
Fund 5+ long-term biohardening pilots and draft government demand-side deployment playbooks
2027
Continue biohardening pilots and test NPI / building-response playbooks in public settings
2028
Begin wider deployment of biohardening technologies through public-building requirements and code pathways
2029
Push building-code reform, public-building requirements, and NPI / biohardening playbooks for pathogen resistance
2030
Continue deployment of pathogen-resistant building measures and maintain public-building response playbooks
Current Status of the Field
Far-UVC, conventional GUV, filtration, ventilation controls, vapor decontamination, and emergency collective-protection approaches are all technically plausible, but field evidence and operating standards vary widely.
Building codes and public-building procurement rarely require pathogen resistance today, leaving adoption dependent on voluntary owners and isolated pilots.
The bottleneck is demand creation and operational guidance: governments need standards and playbooks that tell buildings what to do when surveillance or outbreak signals change.
The Problem
The indoor spaces where people spend much of their time — schools, offices, transit systems, and healthcare facilities — are also where respiratory pathogens spread efficiently. Yet very few of these spaces are designed to suppress airborne transmission. Technologies such as far-UVC, improved filtration, and emergency air-disinfection approaches are promising, but evidence, standards, and deployment models remain incomplete.
The Solution
The near-term priority is to strengthen the evidence base and run real-world pilots so that promising technologies can move more quickly toward wider deployment. Companies can build and install technologies, but governments are the essential demand-side actors: mandates, public-building requirements, procurement standards, and building-code reforms determine whether deployment reaches scale. Long-term policy and legal changes will take time, but the path to them begins with high-quality safety research, long-term monitoring, well-designed demonstrations in high-traffic settings, and NPI / biohardening playbooks that convert threat signals into building actions. The ultimate aim is not only better pilots, but also the standards, guidance, and incentives needed for pathogen-resistant construction, emergency building adaptation, and protection of critical infrastructure.
Objectives
- ◆75%+ of high-traffic indoor spaces incorporate pathogen-resistant technologies that substantially reduce airborne transmission
- ◆Far-UVC safety and large-scale effectiveness studies are completed and exposure guidelines are established to enable widespread deployment
- ◆Guidance materials or tools are developed to enable adaptation of buildings to significantly reduce pathogen transmission within two weeks of a pandemic
- ◆Government demand-side levers — mandates, public-building requirements, procurement standards, and building-code reforms — encourage pathogen-resistant construction and retrofit
- ◆NPI and biohardening playbooks translate surveillance and threat signals into concrete building actions, including ventilation changes, filtration, germicidal irradiation, occupancy measures, and decontamination protocols
- ◆Rapid decontamination capabilities for critical infrastructure include conventional GUV, vapor decontamination options such as HOCl, ClO2, dry hydrogen peroxide, hydroxyl radicals, and improvised collective protection where appropriate
Urgent 2026 Milestone
Fund more than five long-term pilot deployments of germicidal lighting with epidemiological monitoring.
Long-term Targets
Critical-space clean-air coverage
Year-by-Year
Philanthropy
- •Fund comprehensive far-UVC safety research and long-term pilot deployments with epidemiological monitoring
- •Fund development and testing of improvised air-filtration protocols and vapor-based air decontamination as emergency biohardening measures
Private Sector
- •Support germicidal-lighting research and deployment partnerships
- •Develop and install pilot technologies in real-world sites, including filtration, conventional GUV, and emergency decontamination options where appropriate
Government
- •Establish far-UVC safety guidance and authorize pilot programs in public buildings
- •Draft demand-side deployment levers, including public-building requirements, procurement standards, and building-code pathways
- •Support emergency adaptation guidance for air-quality and decontamination measures
- •Begin preparing for building-code reforms and critical-infrastructure biohardening over time
Philanthropy
- •Continue building PPE stockpiles held in trust for public distribution and fund readiness exercises for 24-hour delivery
- •Continue far-UVC and other biohardening pilots while strengthening the evidence base and playbooks
- •Continue catalyzing government-led MCM platform work, distributed manufacturing, market incentives, and clinical trial preparedness
- •Fund concrete operational response exercises and communication-playbook development
Private Sector
- •Expand PPE manufacturing and stockpile support
- •Continue deployment support for germicidal-lighting, filtration, decontamination, and air-quality pilots
- •Advance candidate MCMs through development milestones and maintain rapid trial and manufacturing readiness
- •Participate in concrete public-private response exercises tied to named playbooks
Government
- •Expand respiratory PPE stockpiles and exercise rapid-delivery systems
- •Continue regulatory and policy support for biohardening pilots, public-building standards, and emergency adaptation protocols
- •Lead development of vaccine, diagnostic, and therapeutic platforms, distributed manufacturing agreements, and emergency pathways
- •Lead government participation in exercises for specific coordination products and playbooks
Philanthropy
- •Continue funding stockpile expansion toward broad essential-workforce coverage and support surge-capacity agreements
- •Fund wider deployment of biohardening technologies, especially in underserved areas, public buildings, and critical settings
- •Support late-stage development of priority MCM platforms, distributed manufacturing, market incentives, and end-to-end exercises validating progress toward 100-day capability
- •Fund international response exercises testing specific activation, procurement, communication, and playbook workflows
Private Sector
- •Maintain or expand surge capacity for PPE and support broader logistics readiness
- •Manufacture and install air-decontamination and biohardening technologies at larger scale
- •Maintain geographically distributed manufacturing readiness for platform vaccine surge production and support scale-up of diagnostics and therapeutics
- •Support cross-border coordination mechanisms for specific products and services
Government
- •Expand national stockpiles and secure surge manufacturing agreements for PPE
- •Adopt or prepare pathogen-resistant building-code reforms, public-building requirements, and government-building retrofits
- •Fund and exercise end-to-end 100-day response capability, distributed manufacturing agreements, and demand guarantees for MCMs
- •Negotiate and test targeted multinational coordination protocols without depending on a new permanent command body
Philanthropy
- •Continue targeted support for final stockpile expansion, public distribution readiness, MCM validation, and communication readiness
- •Support harder-to-fund coordination, playbook testing, and stress-testing work that improves real-world performance
Private Sector
- •Maintain surge capacity and operational readiness for PPE, diagnostics, therapeutics, and vaccines
- •Continue deployment of pathogen-resistant technologies, distributed manufacturing readiness, and annual readiness exercises
Government
- •Maintain stockpiles sufficient for 90+ days of essential-workforce protection at pandemic onset in priority jurisdictions
- •Maintain tested 24-hour PPE distribution systems
- •Exercise full 100-day MCM response capability and specific multinational coordination workflows capable of activation within hours
Philanthropy
- •Support hard-to-fund maintenance, exercises, and improvement work across PPE, built environment, MCM readiness, market incentives, and coordination playbooks
Private Sector
- •Maintain surge manufacturing, resilient supply chains, and operational readiness across PPE and MCMs
Government
- •Maintain stockpiles, manufacturing agreements, demand guarantees, building adaptation, and exercised response workflows as part of permanent national and international readiness architecture
Who's Working on This
Funder
regranting
Implementers
research
research